Autopsy report · NCT02392572

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

“\<75% participants”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 10 years 9 months before it stopped.
• 58 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome

Interventions

Akt/ERK Inhibitor ONC201; Venetoclax

Participants

58

Sites

1

Countries

United States

Trials that died the same way

• Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
  “\<75% participation” (87% match in meaning)
• Vapocoolant Analgesia for Breast Lymphoscintigraphy
  “\<75% accrued participants” (78% match in meaning)
• Amikacin Pharmacokinetic Profile in Plasma and Tissue After an Administration Using Impregnated Dressings in Burned Patient Population
  “not enough participants to include” (61% match in meaning)
• Impact of Daylight on Patients With Acute Myocardial Infarction
  “not enough participants” (60% match in meaning)
• Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery
  “low participation rate” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.